C ytokine immunotherapy is being increasingly used as an adjunct to conventional chemotherapy/radiotherapy to treat minimal residual disease. Interleukin-12 (IL-12), a heterodimeric cytokine composed of covalently linked p35 and p40 chains 1, 2 and secreted by antigen-presenting cells 3, 4 during the early stages of an immune response, has been demonstrated to exhibit multiple immunomodulatory activities. The various immunostimulatory activities of IL-12 include the secretion of interferon-␥ (IFN-␥) from naive and activated T and natural killer (NK) cells; 5, 6 enhancement of the cytotoxic activity of NK cells, cytotoxic T lymphocytes, lymphokine activated killer cells; [7] [8] [9] and the proliferation of preactivated T cells and NK cells. 10, 11 In addition, IL-12 has been shown to promote the differentiation of immature type 0 T helper (Th0) cells into Th1 cells [12] [13] [14] and to synergize with hematopoietic growth factors (stem cell factor, IL-3, and IL-11) to enhance the survival and proliferation of early multipotent hematopoietic progenitor cells and lineage-committed precursor cells in vitro. 15 Because IL-12 favors the differentiation of Th1 cells that produce cytokines that are necessary for the development of cell-mediated immune responses, IL-12 has been speculated to play a prominent role in the defense against tumors. Indeed, IL-12 has been examined for its antitumoral effects in a number of murine tumor models of local and metastatic disease. Systemic administration of IL-12 was shown to cause tumor regression and prolong the survival of animals implanted with tumor cells.
16 -21 IL-12 was also shown to reduce the metastatic spread of experimental tumors. 16, 20, 21 The antitumoral effects of IL-12 were observed at doses close to the maximum tolerated dose for mice (e.g., 0.1-1 g daily). 16 To increase the antitumoral effects of IL-12 without the dose-limiting toxicity observed via systemic administration, IL-12 was administered by peritumoral injections 16 or by injecting IL-12-transfected fibroblasts into tumors. 22 In addition, IL-12-transfected tumor cell vaccines and local delivery of the IL-12 gene as naked DNA by gene gun or in viral vectors have also been investigated. [23] [24] [25] [26] Most of these strategies have resulted in improved antitumoral effects, ranging from complete tumor regression to significantly increased survival of mice implanted with tumor cells. Studies on the mechanism of the antitumoral effect of IL-12 have implicated T cells as critical immune effector cells; however, the involvement of specific T-cell subsets (CD4 ϩ or CD8 ϩ ) has varied with the tumor system studied. [27] [28] [29] In most of the experimental studies in which IL-12 has been tested for antitumoral activity, tumors were grown as solid lesions. There are very few studies in which the tumor inhibitory effect of IL-12 against hematological malignancies (i.e., leukemia and lymphomas) has been examined. 30 -32 The efficacy of hematopoietic progenitor cells transduced with IL-12 genes against residual leukemia has not been investigated. Based on the considerable published data on the antitumoral effects of IL-12, we have speculated that IL-12 gene therapy with hematopoietic progenitor cells genetically modified to secrete IL-12 might eliminate the residual leukemic disease that remains after conventional chemotherapy. In the present study, we examined the expression of IL-12 genes in hematopoietic progenitor cells and tested the biological and anti-leukemic effects of transduced cells in vivo. The results demonstrate that the 32Dc13 myeloid progenitor cell line transduced with murine IL-12 (mIL-12) cDNAs coding for p35 and p40 polypeptides (32DIL-12 cells) stably expresses and secretes biologically active mIL-12. Administration of transduced cells (32DIL-12 cells) induced IFN-␥ secretion and NK activity in vivo and inhibited the progression of leukemia in ϳ40% of the mice implanted with a lethal dose of 32Dp210 myeloid leukemia cells.
MATERIALS AND METHODS

Mice
We purchased 8-to 10-week-old male C3H mice from Taconic Laboratories (Germantown, NY). Mice were maintained in the Bioresource Facility of the Henry Ford Health System at One Ford Place. All animals were given mouse chow and acidified water ad libitum. Mice were housed for at least 1 week before experimental use; age-matched animals were used within any given experiment.
Cell lines
The mIL-3-dependent 32Dc13 myeloid progenitor cell line (nontransformed) was maintained in Iscove's modified Dulbecco's medium (IMDM) supplemented with 10% fetal bovine sera (FBS) and 20% Wehi-3B cell conditioned medium (CM). 32Dp210 leukemia cells, which were derived from the 32Dc13 cell line by transfection with the BCR/ABL oncogene, were provided by Dr. D. Fowler (National Cancer Institute, Bethesda, Md) and maintained in vitro in RPMI 1640 supplemented with 10% FBS. Both cell lines were subcultured at 4 days by seeding 5 ϫ 10 5 cells in 10 mL of culture medium in 25-cm 2 tissue culture flasks.
Nonclonal progenitor cells
Primary cultures of hematopoietic progenitor cells were initiated with bone marrow (BM) cells obtained 72 hours after treating mice with 5-fluorouracil (5-FU). Red blood cells were removed from the BM cells, and 2 ϫ 10 6 nucleated cells were seeded into each 50-mL tissue culture flask in 5 mL of IMDM supplemented with 10% FBS, 20% Wehi-3B cell CM, mIL-3 (2 ng/mL), mouse stem cell factor (50 ng/mL), and human IL-6 (0.2 ng/mL), referred as complete IMDM hereafter. After 5 days of incubation, nonadherent cells were resuspended in fresh IMDM, transferred to new flasks, and maintained by serial passaging.
Transduction of progenitor cells with mIL-12 genes
We introduced the mIL-12 genes into progenitor cells using the modified MFG retroviral vector known as TFG-mIL-12-Neo (Fig 1) , kindly provided by Dr. Hideaki Tahara of the Pittsburgh Cancer Institute (Pittsburgh, Penn). The polycistronic TFG-mIL-12-Neo vector, as previously described elsewhere, 24 contains the cDNAs of p35 and p40 of mIL-12. Retroviral supernatant was generated by transfecting the TFGmIL-12-Neo proviral construct into the CRIP packaging line. The 32Dc13 progenitor cell line or BM progenitor cells (5-FU BM cells) (2 ϫ 10 6 cells/mL) were infected with retroviral supernatant (5 ϫ 10 5 colony-forming units/mL) in the presence of polybrene (8 mg/mL) for 24 hours. Cells were washed twice in phosphate-buffered saline (PBS) and resuspended in 5 mL of complete IMDM culture medium containing G418 (1 mg/mL). Cells were cultured for 2 weeks to select G418-resistant cells. Resistant cells were further expanded in complete IMDM in the presence of G418 (1 mg/mL) to study transgene expression and the in vivo effects of transduced cells. The transduction efficiency of both clonal 32Dc13 cells and primary BM hematopoietic progenitor cells ranged from 40% to 50%.
Enzyme-linked immunosorbent assay (ELISA) for mIL-12 and IFN-␥
The quantitation of mIL-12 secreted by transduced cells and IFN-␥ produced in response to the IL-12 secreted by transduced cells was carried out by using commercially available cytokine specific ELISA kits according to instructions provided by the vendor (Biosource International, Camarillo, Calif). For IL-12 secretion, 32DIL-12-transduced cells were cultured at 1 ϫ 10 6 cells/mL of tissue culture medium for 24 hours at 37°C. For IFN-␥ production, spleens were removed from mice injected with 32DIL-12 cells and 1 ϫ 10 6 cells/mL were cultured for 24 hours. Cultures were centrifuged at 2000 ϫ g GAUTAM, XU, DUMAGUIN, ET AL: IL-12 GENE THERAPY OF LEUKEMIA for 10 minutes, and supernatant was collected and stored at Ϫ70°C until being used for the measurement of cytokines.
Bioassay of IL-12 activity
The bioactivity of the mIL-12 secreted by transduced 32DIL-12 cells was determined according to the method of Mattner et al 33 by measuring the proliferation of phytohemagglutinin (PHA)/IL-2-preactivated murine splenocytes. Briefly, spleen cells (5 ϫ 10 6 cells/mL) were cultured in complete RPMI 1640 containing PHA (10 g/mL) and mIL-2 (10 ng/mL) at 37°C for 3 days. At the end of the incubation period, cells were harvested, washed two times with PBS, and resuspended in RPMI 1640 medium at 0.5 ϫ 10 6 cells/mL. Next, 0.1 mL of cells (5 ϫ 10 4 cells) was added to each well of a flat-bottom, 96-well tissue culture plate containing 0.1 mL of RPMI 1640 or culture supernatant conditioned by nontransduced 32Dc13 or transduced 32DIL-12 cells (1 ϫ 10 6 cells/mL/24 hours) or recombinant mIL-12 (rmIL-12) dissolved in RPMI 1640 (1 ng/mL). All samples were prepared in triplicate. Cells were cultured for 48 hours, and 0.5 Ci of [ 3 H]thymidine (specific activity: 74 Ci/mmol) was added to each well for 8 hours. The cultures were harvested with an automatic cell harvester (Skatron, Sterling, Va) using distilled water. The amount of radioactivity incorporated into DNA was determined by liquid scintillation counting. The stimulation index (SI) was calculated by dividing the cpm of experimental cultures by the cpm of medium control cultures.
Cytotoxicity assay
The cytotoxicity mediated by the splenic NK cells was deter- Cr-labeled target cells were added to each well of a roundbottom, 96-well microtiter plate in triplicate. Plates were centrifuged at 50 ϫ g for 1 minute and incubated at 37°C for 4 hours. After incubation, the plates were spun again at 200 ϫ g for 5 minutes; next, 100 L of the supernatant was removed from each well, and the amount of radioactivity released was determined. 
Anti-leukemic effect of IL-12-secreting progenitor cells
To determine the effect of 32DIL-12 cells on the progression of leukemia, mice were injected with 2.5 ϫ 10 3 32Dp210 leukemia cells intravenously (i.v.). This dose of leukemia cells consistently results in 100% mortality within 11-16 days if mice are left untreated. A group of control mice (n ϭ 8) injected with leukemia cells was left untreated, whereas a second group of mice (n ϭ 10) was administered 32DIL-12 cells i.v. A total of 4.5 ϫ 10 7 32DIL-12 cells were injected into each mouse in three equal doses on days 1, 4, and 7 after injection of leukemia cells. Mice were monitored for survival, and those who died were subjected to postmortem examination to confirm the presence of leukemic growth in spleen and liver.
RESULTS
Transduction of hematopoietic progenitor cells with mIL-12 genes IL-12 genes were transduced into the nontransformed myeloid progenitor cell line 32Dc13 and into 5-FU BM cells using a polycistronic retroviral vector that contains the cDNAs coding for p40 and p35 IL-12 chains (Fig 1) . Progenitor cells were incubated in retroviral supernatant (5 ϫ 10 5 colony-forming units/mL) for 24 hours at 37°C. After selection and expansion of G418-resistant cells, IL-12 gene integration (p40) and the secretion of IL-12 protein were analyzed by polymerase chain reaction (PCR) and ELISA, respectively. DNA isolated from transduced cells (both 32Dc13 and 5-FU BM cells), when amplified using p40-specific primers, showed the amplified PCR product of the expected size (1025 bp) (Fig 2, lanes 3 and 5) . Uninfected cells lacked amplification of the p40 gene under identical conditions (Fig 2,  lanes 2 and 4) . Transduced 32Dc13 (32DIL-12) cells have shown stable integration of mIL-12 genes for Ͼ9 months. In contrast, 5-FU BM cells maintain IL-12 genes for Ͻ2 months.
Next, we examined whether 32DIL-12 cells secrete mIL-12. For this purpose, culture supernatants conditioned by 32DIL-12 cells (1 ϫ 10 6 cells/24 hours) were collected at 1, 3, and 6 months after transduction of cells; the concentration of mIL-12 was measured by mIL-12-specific ELISA. The data presented in Table 1 show that transduced cells secreted high levels of mIL-12 (ϳ3000 pg/mL) over the period studied. Nontransduced cells showed no production of mIL-12. 
IL-12 produced by transduced progenitor cells is biologically active
To determine whether the mIL-12 secreted by transduced cells is biologically active, we examined the culture supernatant of 32DIL-12 cells for its ability to induce the proliferation of PHA-activated spleen cells and to induce the secretion of IFN-␥ in normal spleen cells. As shown in Figure 3 , the culture supernatant (50%) conditioned by nontransduced 32Dc13 cells induced insignificant proliferation of activated spleen cells (SI ϭ 1.2). In contrast, the supernatant (50%) conditioned by 32DIL-12 cells induced significant proliferation of mitogen-preactivated spleen cells (SI ϭ 13.3), as did rmIL-12 at a concentration of 1 ng/mL (SI ϭ 18.2).
The bioactivity of the IL-12 produced by transduced cells was also tested for its induction of IFN-␥ production by spleen cells. For this purpose, spleen cells (1 ϫ 10 6 cells/mL) were incubated for 48 hours in medium alone or in medium containing supernatant (50%) conditioned by 32Dc13 or 32DIL-12 cells (1 ϫ 10 6 cells/ mL/24 hours). Supernatant was also collected from cultures of spleen cells incubated with rmIL-12 (5 ng/ mL). The concentration of IFN-␥ in supernatants was determined by ELISA. The data presented in Table 2 demonstrate that spleen cells cultured in medium alone or containing supernatant conditioned by nontransduced 32Dc13 cells secrete a negligible amount of mIL-12. Conversely, spleen cells cultured in the presence of 32DIL-12 cell supernatant produced significant amounts of IFN-␥, which was comparable with that induced by rmIL-12. These data indicate that the IL-12 produced by transduced cells is capable of inducing the production of IFN-␥ in spleen cells.
Overall, these data demonstrate that hematopoietic progenitor cells can be transduced with IL-12 genes using a MFG-based retroviral vector to stably produce abundant amounts of biologically active IL-12 protein.
Transplantation of IL-12-secreting 32 IL-12 cells
To assess the distribution and the effects of IL-12 secreted by transduced cells in vivo, mice were injected with 4.5 ϫ 10 7 32DIL-12 cells i.v. For distribution of transduced cells, DNA was isolated from BM and spleen cells 3 and 10 days after injection of cells. DNA was amplified by PCR using p40-specific primers and fractionated on 1% DNA agarose gel. The amplified p40 IL-12 gene fragment of the expected size (1025 bp) was present in the BM and spleen cells that were obtained on day 3 (Fig 4 lanes 3 and 6) , but not on day 10 (Fig 4,  lanes 4 and 7) after injection of transduced cells. In some mice injected with transduced cells, the p40 IL-12 gene could also be detected in the liver (data not shown). p40 was not detected in the BM and spleen cells of normal mice not injected with 32DIL-12 cells (Fig 4, lanes 2 and  5) .
32DIL-12 cells induce IFN-␥ production and activation of NK cells in vivo IFN-␥ induction. rIL-12 is a potent inducer of IFN-␥ in vivo. 34 To determine whether the IL-12 produced by Table 3 reveal that the IFN-␥ level in the sera increased rapidly, reaching a peak at 24 hours and then dropping to an undetectable level by day 5. In the spleen cell culture supernatant, the highest level of IFN-␥ was observed on day 2, and subsequently returned to the normal level by day 10. Although the production of IFN-␥ by BM cells followed a time course that was similar to that seen for spleen cells, the concentration of IFN-␥ by BM cells was roughly 10 times less compared with the spleen cells (data not shown). Normal mouse serum or normal spleen or BM cell culture supernatant had little or no detectable IFN-␥. These data demonstrate a rapid induction of IFN-␥ production in vivo in response to the IL-12 secreted by 32DIL-12 cells.
NK response. rIL-12 also induces activation of NK cells in vivo. 34, 35 The in vivo activation of NK cell activity in response to the IL-12 secreted by transduced 32DIL-12 cells was measured in a cell cytotoxicity assay using 51 Cr-labeled NK-sensitive YAC-1 cells. For this purpose, mice were injected with 4.5 ϫ 10 7 32DIL-12-transduced cells i.v. Spleen and BM cells recovered on days 1, 2, 3, and 5 after injection of transduced cells were tested for NK cell-mediated cytotoxicity at effector to target (E:T) ratios of 100:1 to 25:1. The data from a representative experiment (n ϭ 3) are shown in Figure 5 , A and B. It is apparent from these data that administration of 32DIL-12-transduced cells to mice results in the activation of a cellular cytotoxic response in spleen cells against NK-sensitive YAC-1 target cells (Fig 5A) . Spleen cell-mediated cytotoxicity was maximal on day 2 (ϳ65%) at an E:T ratio of 100:1, although a significant level of cytotoxicity could be detected on days 1 and 5. A similar time course of development of a cytotoxic response against YAC-1 cells was observed in BM cells ( Fig 5B) ; however, the percentage of cytotoxicity with BM cells was somewhat less (ϳ40%, E:T ratio of 100:1) compared with spleen cells. Both spleen and BM cells obtained 10 days after injection of 32DIL-12 cells were non-cytolytic (data not shown). Figure 7 , 32Dp210 leukemia cells were found to be sensitive to lysis by both spleen (Fig 7A) and BM (Fig 7B) cells of animals injected with 32DIL-12 cells in all three experiments. The time course of the development and the level of spleen and BM cell-mediated cytotoxicity against 32Dp210 leukemia were very comparable with that observed against NK cell-sensitive YAC-1 target cells (Fig 5, A and B) . Taken together, these findings indicate that 32Dp210 leukemia cells are sensitive to IFN-␥ and NK cells, both of which are activated in response to IL-12-secreting 32DIL-12 cells.
IFN-␥ inhibits clonal growth of 32Dp210 leukemia cells
leukemia cells. As shown in
32DIL-12 cells inhibit leukemia in vivo
To investigate the therapeutic efficacy of 32DIL-12 cells against 32Dp210 myeloid leukemia, mice were injected i.v. with 2.5 ϫ 10 3 32Dp210 leukemia cells or 32Dp210 cells followed by 4.5 ϫ 10 7 32DIL-12 cells in three equal doses on days 1, 4, and 7. Mice were monitored for survival, and deaths due to leukemia were confirmed by the presence of metastatic disease in the liver and spleen upon postmortem examination. All mice injected with 32Dp210 leukemia cells alone (n ϭ 8) died between day 11 and day 15, with a mean survival time of 12.8 Ϯ 1.8 days (Fig 8) . A total of 6 of 10 mice that were administered 32DIL-12 cells also died (mean survival time of 16.3 Ϯ 1 days). However, four mice (40%) in this group were alive on day 60. These mice were killed and were found to be free of visible metastatic disease in the spleen or liver. These data demonstrate the anti-leukemic effect of 32DIL-12 cells that results in disease-free survival in a sizable fraction of mice challenged with a lethal dose of 32Dp210 leukemia cells.
DISCUSSION
Minimal residual disease presents a major obstacle in achieving long-term, disease-free survival in patients treated with conventional chemotherapy and/or radiotherapy for hematological malignant disease. Immunotherapy with cytokines as an adjunct to conventional cancer therapies has been gaining popularity in recent years. However, systemic therapy with cytokines is asso- Cr-labeled YAC-1 target cells for 4 hours at 37°C at E:T ratios of 100:1, 50:1, and 25:1 in duplicate. The amount of 51 Cr radioactivity released was determined, and the percentage of cytotoxicity was calculated as described in Materials and Methods. The spontaneous release of radioactivity was Ͻ15%. Similar results were obtained in three separate experiments. ciated with severe toxic side effects. In an effort to optimize the antitumoral effect and to minimize the toxic side effects of cytokines, various gene therapy approaches, including the use of transfected tumor cell vaccines and local delivery of cytokine genes as naked DNA to tumors growing as solid lesions, have been tested. [23] [24] [25] [26] In contrast to numerous reports of antitumoral and antimetastatic effects of IL-12 protein or IL-12 gene therapy with transduced tumor cells against solid lesions, very little is known about the efficacy of IL-12 against hematological tumors. Because IL-12 gene therapy has shown promising antitumoral activity in various solid tumor models, 16 -21 we sought to develop an IL-12-based consolidating adjuvant therapy for residual leukemia using hematopoietic progenitor cells to deliver IL-12 to the sites where residual leukemia cells are most likely to be present (i.e., BM, spleen, liver). In this study, we demonstrate that by using a polycistronic retroviral vector, both clonal (32Dc13) and primary (5-FU BM) hematopoietic progenitor cells can be transduced with IL-12 genes coding for p40 and p35 chains. Extensive analysis of 32Dc13 myeloid progenitor cells transduced with IL-12 genes has revealed stable transgene integration and expression, as evidenced by the continuous secretion of significant amounts of IL-12 protein by transduced cells over Ͼ9 months. The IL-12 secreted by 32DIL-12 cells is biologically active, because it induced a severalfold increase in the proliferation of mitogen-activated spleen lymphocytes and in the production of IFN-␥ by normal spleen cells. Furthermore, we investigated whether the transplantation of transduced cells would mediate the reported biological effects of IL-12 in vivo (e.g., IFN-␥ production and NK cell activation). We have shown that after i.v. injection, transduced cells were evident in the BM and spleen on day 3 but not on day 10. Contrary to the long-term stable expression of IL-12 genes in 32Dc13 progenitors in vitro, transient and short-term detection of transduced cells in vivo may be related to the fact that transduced cells were injected into nonirradiated mice; therefore, only a small fraction of these cells could migrate to the sites examined. In addition, because 32DIL-12 cells depend upon IL-3 for their survival in vitro, requisite levels of IL-3 may not be available in vivo to sustain long-term survival of 32DIL-12 cells. The administration of IL-12-secreting 32Dc13 cells (4.5 ϫ 10 7 cells) was well tolerated, because it produced no measurable toxicity (i.e., body weight loss, lethargy, intestinal bleeding, etc.), which has been reported in animals after systemic IL-12 therapy. 39 Among the several immunomodulatory activities of IL-12, its ability to induce the production of IFN-␥ and activation of NK cells in vivo is the most pronounced. 34, 35 We investigated whether injection of IL-12-transduced progenitor cells (32DIL-12 cells) into mice would also induce these immunological responses. Mice injected with IL-12-secreting cells were found to have significantly increased levels of IFN-␥ in their serum within 24 -48 hours. In addition, spleen cells from injected mice were also found to secrete large amounts of IFN-␥ in vitro. Although BM cells from injected mice were also found to secrete IFN-␥, the amount of IFN-␥ produced by BM cells was less than that produced by spleen cells (data not shown). Transduced cells also induced a strong cytotoxic activity in spleen and BM cells against NK-sensitive YAC-1 target cells (ϳ60% lysis). In addition to YAC-1 target cells, both spleen and BM cells from mice injected with IL-12-secreting progenitor cells expressed significant cytotoxicity against the myeloid leukemia cell line 32Dp210. The time course of the induction of IFN-␥ and NK activity in vivo by 32DIL-12 cells correlated with the detection of transduced cells in vivo. Both IFN-␥ and NK activity peaked over 24 -48 hours, a time at which transduced cells are also detected, and returned to undetectable levels by day 10, which also coincides with the time at which transduced cells become undetectable. Overall, the studies described here demonstrate that hematopoietic progenitor cells can be successfully transduced with IL-12 genes, and that injection of transduced cells into mice results in increased levels of IFN-␥ and in NK cell activity in vivo.
In most studies, the antitumoral effects of IL-12 were reported to be associated with an increase in the levels of IFN-␥ and with an augmentation of NK activity. 17,36 -38 Because both these responses are induced in vivo by injecting mice with 32DIL-12-transduced cells, we determined the effect of transduced cells on the progression of leukemia in mice challenged with a lethal dose of 32Dp210 cells. 32Dp210 cells produce an acute myeloid leukemia-like condition in C3H mice, and we have shown previously that as few as 10 2 32Dp210 cells kill mice in ϳ4 weeks. To investigate the anti-leukemic activity of 32DIL-12 cells against 32Dp210 leukemia, mice were injected with 2.5 ϫ 10 3 32Dp210 cells followed by 4.5 ϫ 10 7 32DIL-12 cells and actuarial leukemia-free survival was determined. Although 60% of the mice administered IL-12 gene therapy with transduced progenitor cells died because of progressive disease, 40% of the treated mice were alive and disease free on day 60 and were considered cured. Even mice that were treated but succumbed to the disease showed a survival advantage over the mice that were not treated. These data indicate that IL-12 gene therapy with hematopoietic progenitor cells may prove beneficial, at least against leukemias that are sensitive to IFN-␥ and NK cells.
The production of IFN-␥ and the activation of NK activity after injection of 32DIL-12 cells provides an indication of the mechanism of the anti-leukemic effect of IL-12 gene therapy in the present studies. Other immune cellular events have also been shown to be important in the IL-12-mediated rejection of tumors. Both CD8 ϩ and CD4 ϩ T-cell subsets have been shown to infiltrate tumors with local IL-12 therapy; [27] [28] [29] however, CD8
ϩ T cells were found to be critical in the destruction of tumors. 28 In addition, activated macrophages have also been implicated in tumor regression after IL-12 therapy. 40 Whether these immune effector mechanisms are also activated and participate in the anti-leukemic activity IL-12 gene therapy with hematopoietic progenitor cells as shown in this study remains to be investigated. To increase the efficacy of progenitor cell-based IL-12 gene therapy of leukemia, we are currently testing several variations in the treatment protocol (e.g., cell dose, timing of 32DIL-12 cell injection relative to challenge with leukemia cells, etc.), including the administration of transduced cells after debulking of leukemia burden with cytotoxic chemotherapy. In summary, we have demonstrated that hematopoietic progenitor cells can be efficiently transduced with IL-12 genes, and that injection of transduced cells into mice induces the production of IFN-␥ and NK cellmediated cytotoxicity. Furthermore, IL-12-secreting transduced progenitor cells inhibit the progression of leukemia in a sizable fraction of mice challenged with a lethal dose of myeloid leukemia cells.
